AksharChem Q2 FY27 standalone revenue Rs 160.48 cr, PAT turns positive
For Q2 FY27, AksharChem standalone revenue was Rs 160.48 cr and PAT Rs 13.32 cr versus a loss of Rs (1.37) cr a year ago.
Key takeaways
- Revenue from operations Rs 160.48 cr vs Rs 89.30 cr a year ago.
- Total income Rs 160.52 cr vs Rs 89.34 cr in the corresponding quarter.
- PAT Rs 13.32 cr vs loss of Rs (1.37) cr in Q2 FY26.
- PBT before exceptional items Rs 14.09 cr vs Rs (3.10) cr a year earlier.
- Basic and diluted EPS 16.58 vs (1.70) in the corresponding prior quarter.
Q2 FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 160.48 cr | Rs 89.30 cr | +79.7% |
| PAT | Rs 13.32 cr | Rs (1.37) cr | N/A |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 8.30% of revenue, up 983 bps from -1.53%.
- Revenue rose 79.7% while total expenses rose 58.4%.
• Basis: Standalone unaudited statement of financial results for the quarter ended 30-09-2026, as per the statement of financial results.
• Revenue from Operations (Q2 FY27 vs Q2 FY26): Rs 160.48 cr vs Rs 89.30 cr.
• Other Income: Rs 0.0341 cr vs Rs 0.034 cr.
• Total Income (I+II): Rs 160.52 cr vs Rs 89.34 cr.
• Cost of materials consumed: Rs 84.45 cr vs Rs 44.78 cr.
• Purchase of Stock-in-Trade: Rs 2.87 cr vs Rs 3.28 cr.
• Changes in inventories of finished goods, work-in-progress and Stock-in-Trade: Rs 10.32 cr vs Rs 4.34 cr.
• Employee benefits expense: Rs 4.49 cr vs Rs 3.93 cr.
• Power & Fuel: Rs 17.30 cr vs Rs 13.55 cr.
• Finance costs: Rs 2.47 cr vs Rs 1.38 cr.
• Depreciation and amortisation expenses: Rs 4.45 cr vs Rs 4.11 cr.
• Other expenses: Rs 20.08 cr vs Rs 17.08 cr.
• Total Expenses: Rs 146.43 cr vs Rs 92.44 cr.
• Profit / (Loss) before exceptional items and tax (PBT before exceptional items): Rs 14.09 cr vs Rs (3.10) cr.
• Exceptional Items: Rs - vs Rs 1.70 cr.
• Profit / (Loss) before tax (PBT): Rs 14.09 cr vs Rs (1.40) cr.
• Total tax expenses: Rs 0.7637 cr vs Rs (0.0357) cr.
• Profit / (Loss) for the period from continuing operations (PAT): Rs 13.32 cr vs Rs (1.37) cr.
• Total Comprehensive Income for the period: Rs 12.98 cr vs Rs (1.67) cr.
• Paid up Equity Share Capital (Face Value of Rs. 10/- each): Rs 8.03 cr vs Rs 8.03 cr.
• Earnings per share – Basic (In Rs.): 16.58 vs (1.70).
• Earnings per share – Diluted (In Rs.): 16.58 vs (1.70).
For the quarter ended 30-09-2026, AksharChem (India) Limited’s standalone revenue from operations, as reported in the statement of financial results, increased to Rs 160.48 cr from Rs 89.30 cr in the corresponding quarter ended 30-09-2025. Total income rose to Rs 160.52 cr from Rs 89.34 cr over the same period.
Total expenses moved to Rs 146.43 cr in Q2 FY27 from Rs 92.44 cr a year earlier, with cost of materials consumed at Rs 84.45 cr versus Rs 44.78 cr, power & fuel at Rs 17.30 cr versus Rs 13.55 cr, and finance costs at Rs 2.47 cr versus Rs 1.38 cr. Profit / (Loss) before exceptional items and tax improved to Rs 14.09 cr from Rs (3.10) cr, and after exceptional items the profit / (loss) before tax was Rs 14.09 cr compared with Rs (1.40) cr in the corresponding prior quarter.
After total tax expenses of Rs 0.7637 cr against Rs (0.0357) cr a year ago, profit / (loss) for the period from continuing operations (PAT) stood at Rs 13.32 cr, compared with a loss of Rs (1.37) cr in the quarter ended 30-09-2025. Total comprehensive income for the period was Rs 12.98 cr versus Rs (1.67) cr. Basic and diluted earnings per share for the quarter were 16.58, against (1.70) in the same quarter of the previous year, on an unchanged paid up equity share capital of Rs 8.03 cr.
Track AksharChem India Ltd-$
Cruxal reads every AksharChem India Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.